BackCD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload
PF-08046044 | SGN-35C is an investigational compound. Its safety and efficacy have not been established
Overview + Rationale
- PF-08046044 |SGN-35C is a CD30-directed ADC with the same mAb backbone as BV, conjugated to a novel TOP1 inhibitor through a glucuronide linker.1
- CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue2
Mechanism of Action
Stage of Development
R/R CD30-Expressing Lymphomas
Phase 1 Monotherapy
This information is current as of February 4th 2025.
BV = Brentuximab vedotin; R/R = relapsed/refractory; TOP1 = topoisomerase I
REFERENCES: 1 Hamblett KJ. Blood. 2023, 142:1440.. 2. Heiser R. MCT. 2023 10.1158/1535-7163.MCT-23-0118; 3. Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06254495 January 16, 2025.